CCTG Clinical Trials
Public Trial Select
Member Trial Select
Protecting Cancer Patients from COVID-19In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients. More >> |
Recently Activated Trials
Member Links
CCTG Announces Initiation of IND.239CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer. More >> |
Planned Trials
Committees Select
CCTG Director Dr. Janet Dancey, elected to Canadian Academy of Health Sciences
The Canadian Cancer Trials Group (CCTG) is pleased to announce that our Director, Dr. Janet Dancey, has been elected to the Canadian Academy of Health Sciences (CAHS), which represents Canadian health sciences internationally and informs solutions that improve the health of all Canadians.
Dr. Dancey is an international leader in cancer clinical trials of experimental therapeutics and has special expertise in new anti-cancer drug development, linking drug and biomarker development, and associated clinical trials methodology, including development of novel trials for patients with rare tumours. As Director, she has advanced CCTG’s research strategy and expanded its portfolio dramatically. A prolific author with an excellent citation record, she is a sought-after speaker, both nationally and internationally.
CCTG Announces Initiation of IND.239
CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer.
More >>
Protecting Cancer Patients from COVID-19
In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients.
More >>
PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020
ENZAMET | CCTG PR17 (NCT02446405) study has been highlighted by the American Society of Clinical Oncology (ASCO) 2020 annual report as a major advance in cancer treatment. The results were first presented at ASCO 2019, the trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer.
More >>
An interview with Senior Investigator Annette Hay
Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials.
More >>
Palliative and supportive care presentation at ESMO 2019
Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by CCTG also used complementary medicines.
More >>
Cell Therapy’s Promise for Canadians Must Include Access
An emerging form of immunotherapy, called adoptive cell transfer, has the potential to transform the way in which cancers are treated.
More >>Planned trials
HD11
Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma
Recently activated
The rise of precision medicine
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
More >>
TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancer
Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.
More >>
Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide
Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.
More >>
Canadian Cancer Research Alliance announces award winners
Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award.
More >>Publications
Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience
Breast Cancer Res Treat , 2020
Dent SF;Botros J;Rushton M;Aseyev O;Levine MN;Parulekar WR;OGCOBrien P;Burnell M;Pritchard KI;Chen BE;Shepherd LE;
Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial (ONLINE)
Cancer n/a, 2020
Moku P;Shepherd L;Ali SM;Leitzel K;Parulekar WR;Zhu L;Virk S;Nomikos D;Aparicio S;Gelmon K;Drabick J;Cream L;Halstead ES;Umstead TM;Mckeone D;Polimera H;Maddukuri A;Ali A;Nagabhairu V;Poulose J;Pancholy N;Spiegel H;Chen BE;Lipton A;
The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance)
Cancer Epidemiol Biomarkers Prev 29: 1692, 2020
Cheng E;Zhang S;Ou FS;Mullen B;Ng K;Saltz LB;Niedzwiecki D;Mayer RJ;Mowat RB;Whittom R;Hantel A;Benson A;Atienza D;Messino M;Kindler H;Giovannucci EL;Van Blarigan EL;Meyerhardt JA;Fuchs CS;
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial (ONLINE)
The Lancet , 2020
Parker CC;Clarke NW;Cook AD;Kynaston HG;Petersen PM;Catton C;Cross W;Logue J;Parulekar W;Payne H;Persad R;Pickering H;Saad F;Anderson J;Bahl A;Bottomley D;Brasso K;Chahal R;Cooke PW;Eddy B;Gibbs S;Goh C;Gujral S;Heath C;Henderson A;Jaganathan R;Jakobsen H;James ND;Kanaga Sundaram S;Lees K;Lester J;Lindberg H;Money-Kyrle J;Morris S;O'Sullivan J;Ostler P;Owen L;Patel P;Pope A;Popert R;Raman R;Roder MA;Sayers I;Simms M;Wilson J;Zarkar A;Parmar MKB;Sydes MR;
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial (ONLINE)
JAMA Oncology , 2020
Sridhar SS;Blais N;Tran B;Reaume MN;North SA;Stockler MR;Chi KN;Fleshner NE;Liu G;Robinson JW;Mukherjee SD;Rahim Y;Winquist E;Booth CM;Nguyen NT;Beardsley EK;Alimohamed NS;McDonald GT;Ding K;Parulekar WR;
Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience
Breast Cancer Res Treat , 2020
Dent SF;Botros J;Rushton M;Aseyev O;Levine MN;Parulekar WR;O'Brien P;Burnell M;Pritchard KI;Chen BE;Shepherd LE;
Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial (ONLINE)
Breast Cancer Res Treat , 2020
Ho V;Pasquet R;Luo S;Chen G;Goss P;Tu D;Lazarus P;Richardson H;
Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients
Journal of Neuro-Oncology 149: 65 - 71, 2020
Climans SA;Brandes AA;Cairncross JG;Ding K;Fay M;Laperriere N;Menten J;Nishikawa R;O'Callaghan CJ;Perry JR;Phillips C;Roa W;Wick W;Winch C;Mason WP;